Autres langues AstraZeneca PLC

Actions

AZN

GB0009895292

Produits pharmaceutiques

Marché Fermé - London S.E. 17:35:29 14/09/2026			Varia. 5j.	Varia. 1 janv.
12 154,00 ^GBX	+3,81 %		+1,23 %	-11,86 %

14/09	Les plus fortes baisses à la mi-séance	MT
14/09	L'action Cellectis chute après son repositionnement stratégique dans l'édition génomique in vivo	MT

Autres langues

14/09	Health Care Up on Rotation Into Less Fuel-Sensitive Sectors -- Health Care Roundup
14/09	Top Midday Decliners
14/09	Cellectis Shares Fall After Realigning Focus to Become in Vivo Gene Editing Company
14/09	Schwächer - KI-Sorgen belasten Technologie-Werte
14/09	FTSE 100 outperforms as AI worry hits Wall Street
14/09	European Stocks Close Mixed in Monday Trading; ECB Rates Could Rise as Energy Costs Fuel Inflation
14/09	Leichter - KI-Sicherheitsthematik bewegt Kurse
14/09	AstraZeneca Reports Updated Eight-Year Survival Data For Tagrisso In Adaura Phase III Trial
14/09	AstraZeneca And Daiichi Sankyo Demonstrate Median Progression-Free Survival With Enhertu In Destiny-Lung04 Phase III Trial
14/09	AstraZeneca Provides Update On SERENA-4 Phase III Trial Of Etcamah In Combination With Palbociclib In Upfront First-Line Advanced ER-Positive Breast Cancer
14/09	European Midday Briefing : Chip Stocks Fall on AI Delay Fears
14/09	AstraZeneca Breast Cancer Combination Treatment Misses Main Target in Late-Stage Study
14/09	Leichter - "KI-Aktien" sehr schwach - Roche mit Studienerfolg fest
14/09	Astrazeneca Says Cancer Drugs Enhertu, Tagrisso Show Survival Benefits in Late-Stage Trials
14/09	Morning Meeting: Die KI-Liebe der Märkte bekommt erste Risse
14/09	AstraZeneca Breast-Cancer Drug Misses Goal in Late-Stage Trial
14/09	Astrazeneca-Brustkrebsmedikament verfehlt Ziel in Spätphasenstudie
14/09	UK Stocks-Factors to watch on September 14
14/09	AstraZeneca Says Lung Cancer Drug Tagrisso Sustains Overall Survival Benefit
14/09	AstraZeneca's Phase 3 Trial of Combination Treatment for Breast Cancer Fails to Meet Primary Endpoint
14/09	AstraZeneca, Daiichi report Enhertu benefit in advanced lung cancer
14/09	ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
14/09	TAGRISSO® (osimertinib) demonstrated unprecedented eight-year landmark survival in early-stage EGFR-mutated lung cancer in ADAURA Phase III trial
11/09	AstraZeneca Says Late-Stage Etcamah Breast-Cancer Trial Misses Main Goal
11/09	AstraZeneca's breast cancer pill fails in late-stage trial